Table 2 Cumulative probability of human papillomavirus (HPV) acquisition/reactivation among HIV-positive and HIV-negative women with and without cryotherapy
| Â | Cumulative no. with a newly detected HPV infection (cumulative%) | Â | |||
|---|---|---|---|---|---|
| Â | 6 months | 12 months | 24 months | 36 months | Pvalue for log-rank test |
HIV-negative women | Â | Â | Â | Â | Â |
Total sample: | Â | Â | Â | Â | Â |
   Cryotherapy arm (n = 271) | 15 (5.5) | 21 (7.9) | 25 (9.7) | 28 (11.2) | 0.0004 |
   Control arm (n = 269) | 17 (6.3) | 30 (11.5) | 45 (18.0) | 59 (24.8) |  |
Sexual activity reported during 1 month prior to enrolment or at 1 or 6 months after enrollment: | Â | Â | Â | Â | Â |
   Cryotherapy arm (n = 238)a | 13 (5.5) | 18 (7.7) | 22 (9.7) | 25 (11.3) | 0.002 |
   Control arm (n = 236)b | 16 (6.8) | 27 (11.8) | 42 (19.4) | 56 (27.2) |  |
No sexual activity reported during 1 month prior to enrollment and at 1 and 6 months after enrollment: | Â | Â | Â | Â | Â |
   Cryotherapy arm (n = 31)a | 2 (6.5) | 3 (10.4) | 3 (10.4) | 3 (10.4) | 0.96 |
   Control arm (n = 29)b | 1 (3.5) | 3 (10.3) | 3 (10.3) | 3 (10.3) |  |
HIV-positive women | Â | Â | Â | Â | Â |
Total sample: | Â | Â | Â | Â | Â |
   Cryotherapy arm (n = 38) | 9 (23.7) | 16 (42.1) | 19 (50.8) | 20 (53.7) | 0.8 |
   Control arm (n = 34)c | 7 (20.6) | 14 (42.8) | 15 (46.6) | 16 (50.5) |  |
Sexual activity reported during 1 month prior to enrollment or at 1 or 6 months after enrollment: | Â | Â | Â | Â | Â |
   Cryotherapy arm (n = 33) | 8 (24.2) | 12 (36.4) | 15 (46.4) | 16 (49.8) | 0.65 |
   Control arm (n = 29)c | 7 (24.1) | 14 (49.4) | 15 (54.0) | 15 (54.0) |  |
No sexual activity reported during 1 month prior to enrollment and at 1 and 6 months after enrollment: | Â | Â | Â | Â | Â |
   Cryotherapy arm (n = 5) | 1 (20.0) | 4 (80.0) | 4 (80.0) | 4 (80.0) | 0.08 |
   Control arm (n = 3) | 0 | 0 | 0 | 0 |  |